Dr. Clay Siegall is a renowned Zoologist and the founder and Chief Executive Officer of Seattle Genetics. Dr. Siegall firm Seattle Genetics is based in the Seattle as the name suggests and focuses on the generation of targeted therapy drugs for diseases which for a long time have been ignored and have not received significant mortality improvements.
Education and Professional Background
Dr. Clay Siegall attended The University of Maryland for his Undergraduate Studies and graduated with a Bachelor of Science Degree in Zoology. To advance his Studies, Dr. Siegall continued his education by attending George Washington University where he graduated with a Ph.D. in Genetics.
Dr. Siegall after his education in the year 1998 established his drug manufacturing firm Seattle Genetics. At the helm of the company Dr. Siegall has made tremendous achievement and among them includes the development of the conjugate drug which is an FDA approved drug and today has multiple approved indications. The company besides conjugate has developed a more than 20 drugs some of which are still awaiting approval from FDA. Dr. Siegall has also made a series of strategic partnership with world-renowned drugs manufacturing companies such as Bayer, Genentech, and Pfizer among many others.
Seattle Genetics started as a small Start-Up company, and within a short period, the firm which once had very few researchers has grown to a respected power player in the field of cancer research. Dr. Siegall still has the drive and focus on making Seattle genetics one of the leading manufacturers of drugs not only in the United States but globally. According to Dr. Siegall, targeted therapies drugs are the future of cancer treatment. Dr. Siegall strives to ensure that the old cancer treatment methods such as systemic chemotherapy become a thing of the past.
Dr. Siegall resolves to study and practice medicine was inspired by the power of technology and the desire to overcome diseases that would otherwise lead to death. Dr. Clay Siegall inspiration also came from a personal experience where he was saddened by the brutal treatment method of chemotherapy that a relative of his who had cancer had to undergo. The desire to make money was also a factor for him to start Seattle Genetics.
Things were not all rosy when Dr. Clay established Seattle Genetics. Between 1999 and 2000 the company had not yet broken even and as a result, the operating capital was getting depleted. It almost took the company ten years to become profitable after the launch of its first IPO. According to Dr. Clay Hard is what makes one successful.